REVVITY, INC. is 1.4x more valuable than Bio-Rad Laboratories, Inc. by market capitalization ($11.30 B vs $8.09 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BIO | RVTY |
|---|---|---|
| Market cap | $8.09 B | $11.30 B |
| US-listed rank | #1065 | #873 |
| Revenue (latest FY) | $2.58B | $2.86B |
| Net income (latest FY) | $759.90M | $241.20M |
| Net margin | 29.4% | 8.4% |
| P/E (trailing FY) | 10.6 | 46.8 |
| SEC filings | 1,494 | 1,736 |
REVVITY, INC. is 1.4x more valuable than Bio-Rad Laboratories, Inc. by market capitalization ($11.30 B vs $8.09 B).
In their latest fiscal years, Bio-Rad Laboratories, Inc. reported $2.58B in revenue while REVVITY, INC. reported $2.86B.
Full pages: Bio-Rad Laboratories, Inc. and REVVITY, INC., or browse the full rankings.